It's fair game to bring up a potential flaw in the trial design.
MSB will need to persuade experts to use this product that is much more expensive than current anti-inflammatory injectable agents. And you can be certain they'll be asking the same questions I am.
Cheer for MSB all you want. But it's much better for the company to build a solid case for their product based on good research, rather than one built on hopes and dreams.
I want the products to succeed, as hard as it is for those here to believe it.
Ann: 36-Month Results of Phase 3 Trial in Chronic Low Back Pain, page-170
-
- There are more pages in this discussion • 204 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.045(4.00%) |
Mkt cap ! $1.335B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.18 | $1.13 | $4.980M | 4.315M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 73090 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 27903 | 1 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |